在吸烟引起的COPD模型中,IL-17中和抗体减轻了功能和结构变化
Alyne Riani Moreira1, Camila Uchoa da Silva1, Leticia de Paula Costa Mattos1
1Laboratory of Experimental Therapeutic (LIM 20), Division of Medicine - School of Medicine of Hospital das Clinicas HCFMUSP, Sao Paulo, Sao Paulo, SP, Brazil.
在慢性阻塞性肺病 (COPD) 的小鼠模型中,用中和抗体阻断介素-17 (IL-17) 逆转了肺损伤和炎症. 这表明IL-17抑制剂可能为COPD患者提供治疗选择,即使在疾病发作后.
科学领域:
- 肺病学
- 免疫学
- 药理学
背景情况:
- 吸烟是慢性阻塞性肺病 (COPD) 的首要原因.
- 涉及免疫细胞和Th17细胞因子的炎症反应与COPD的发展和进展有关.
- 在实验模型中,阻断介素-17 (IL-17) 已显示出降低肺损伤炎症的前景.
研究的目的:
- 在香烟烟雾引起的COPD小鼠模型中评估IL-17抑制剂的治疗效果.
- 评估IL-17阻断是否可以逆转COPD中已存在的肺损伤和炎症.
主要方法:
- 在C57BL/6小鼠中暴露在香烟烟雾中6个月以诱导COPD.
- 在第五个月的烟雾暴露期间,进行了IL-17中和抗体治疗.
- 包括:对照组,对照组+抗IL-17,慢性肺炎和慢性肺炎+抗IL-17. 评估了肺部结构,功能和炎症标志物 (IL-17,IL-6,RORγt).
主要成果:
- 在COPD模型小鼠中,平均线性拦截增加,组织弹性和阻尼性降低,证实了COPD.
- 治疗IL-17抗体可以扭转这些肺部结构和功能变化.
- 治疗减少了COPD小鼠的炎症细胞透,IL-17,IL-6表达和RORγt基因表达.
结论:
- 这项研究是首次在吸烟引起的COPD模型中证明IL-17中和抗体治疗的有效性.
- 抗体治疗成功地逆转了已有的肺损伤和炎症,即使是在疾病发作后开始的.
- 具有IL-17中和性的抗体是治疗COPD的潜在策略.
更多相关视频
09:25Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
09:07Author Spotlight: Development and Characterization of an In Vitro Model to Study Chronic Cigarette Smoke Exposure and Its Impact on Airway Epithelial Cells in COPD Research
Published on: July 12, 2024
相关概念视频
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease-I: Introduction
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
